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Table. Procedural outcomes of retrograde CTO PCI
Outcome
Pooled rate
(95% conﬁdence intervals)
Death 0.7%
(0.5%-1.2%)
Urgent CABG 0.7%
(0.4%-1.2%)
Tamponade 1.4%
(1.0%-2.2%)
Collateral perforation 6.9%
(4.6%-10.4%)
Coronary perforation 4.3%
(1.2%-15.4%)
Donor vessel dissection 2%
(0.9%-4.5%)
Stroke 0.5%
(0.2%-1.0%)
MI 3.1%
(0.2%-5.0%)
Q Wave MI 0.6%
(0.4%-1.1%)
Vascular access complications 2%
(0.9%-4.5%)
Contrast nephropathy 1.8%
(0.8%-3.7%)
Wire fracture and equipment entrapment 1.2%
(0.6%-2.5%)
Overall major adverse cardiac events
(composite of death, urgent CABG,
tamponade, Q-wave MI, and stroke)
2%
(1.5%-2.7%)
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Background: To compare the safety and efﬁcacy of biodegradable-polymer (BP)
drug-eluting stents (DES), bare metal stents (BMS), and durable-polymer DES in
patients undergoing coronary revascularization, we performed a systematic review of
randomized controlled trials, and a multiple-treatments network meta-analysis using
a Bayesian framework.
Methods: PubMed, Embase, Cochrane Controlled Trials Register databases, and
relevant websites from the inception of each database to March 2013. Study stents
included BMS, paclitaxel-eluting (PES), sirolimus-eluting (SES), Endeavor zotar-
olimus-eluting (ZES-E), cobalt-chromium everolimus-eluting (CoCr-EES), platinium-
chromium everolimus-eluting (PtCr-EES), Resolute zotarolimus-eluting stents
(ZES-R), and BP biolimus-eluting stents (BP-BES). Among 1,649 potentially relevant
studies, 112 trials comprising 90,084 patients were ﬁnally selected. The principal
safety endpoints were deﬁnite or probable stent thrombosis (ST) and deﬁnite ST
deﬁned according to the Academic Research Consortium within 1 year.
Results: BP-BES (OR, 0.56; 95% credible interval [CrI], 0.33-0.90), SES (OR, 0.53;
95% CrI, 0.38-0.73), CoCr-EES (OR, 0.34; 95% CrI, 0.23-0.52), and PtCr-EES (OR,
0.31; 95% CrI, 0.10-0.90) were superior to BMS in terms of deﬁnite or probable ST
within 1 year. CoCr-EES demonstrated the lowest risk of ST of all stents and tended to
reduce the risk of ST, at all times after stent implantation. CoCr-EES was associated
with lower risk of deﬁnite ST within 1 year than BP-BES (OR, 0.41; 95% CrI, 0.21-
0.76). SES was superior within 1 year but inferior after 1 year to BMS (OR, 1.82; 95%
CrI, 1.05-3.13) regarding the risk of deﬁnite or probable ST. All DES reduced the
need for repeat revascularization, and all but PES reduced the risk of myocardialJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrinfarction compared to BMS. For any comparison between study stents regarding all-
cause death and cardiac death, there were no statistical differences.
Conclusions: Our study suggests that the optimal combination of stent alloy,
geometry, strut thickness, polymer, and drug plays a more important role than the
biodegradability of the polymer itself in determining the safety of DES.
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Background: Newer oral anticoagulants(OACs) have been evaluated in recent trials
as adjunct to dual antiplatelet therapy (DAPT) in the management of high risk acute
coronary syndromes(ACSs). In view of conﬂicting results of these trials, we decided
to perform a meta-analysis of prospective randomized trials evaluating the therapeutic
role of newer OACs in ACS patients.
Methods: We performed a MEDLINE search using all possible combinations of
keywords "factor Xa inhibitor", "direct thrombin inhibitor(DTI)" or "newer antico-
agulant" with keywords "acute coronary syndrome", "non-ST elevation myocardial
infarction" or "ST-elevation myocardial infarction". All abstracts retrieved using
search results were reviewed in detail to identify randomized trials reporting incidence
of death, myocardial infarction, major bleeding & MACE in patients randomized to
placebo &, oral factor Xa or DTI in ACS patients. Studies that did not use DAPT were
excluded. Meta-analysis was performed following the PRISMA statement. Random-
effects model using inverse-variance weighting was used for the primary analyses.
The main measure of association was odds ratio & 95% CI. Study quality, hetero-
geneity & publication bias was evaluated using standard methods. MACE & bleeding
were also separately analyzed in patients on low doses of trial drugs.
Results: A total of 91 abstracts were reviewed. Data from 2 phase III & 4 phase II
randomized controlled trials that met inclusion criteria was used in ﬁnal analysis. A
total of 30,774 patients were included in the primary analysis. There was no decrease
in all-cause mortality[odds ratio:0.9 (0.74-1.1; p:0.32)] but a signiﬁcant decrease in
MACE[0.87(0.76-0.98);p¼0.03] & recurrent MI[0.87(0.76-0.99; p¼0.04)]. There was
a signiﬁcant increase in major bleeding [3.1(2.3-4.1);p<0.001]. Data on outcomes for
low dose was available in 14673 patients across 5 studies & was consistent with those
of the primary analysis with a similar decrease in MACE[0.85(0.74-0.98);p¼0.02] &
increase in major bleeding[3.35(2.1-5.4);p<0.001].
Conclusions: Use of newer OACs as adjunct to DAPT in patients with high risk ACS
reduces risk of recurrent MI & MACE at the risk of threefold increase in major
bleeding.
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Background: Bifurcation lesions are common, and bifurcation PCI is associated with
worse outcomes, including target lesion failure and stent thrombosis (ST). There is
limited data on whether IVUS guidance can improve outcomes compared to angio-
graphic guidance in bifurcation PCI.
Methods: We conducted a meta-analysis of studies that reported long-term outcomes
in IVUS-guided vs. angiography-guided bifurcation PCI.
Results: Five observational studies with 7,123 patients were included. Mean follow-up
time was 28.1 months for IVUS-guided PCI, and 25.7 months for angiography-guided
PCI. Drug eluting stents were used in most cases (80.1%), and left main PCI was
uncommon (9.3%). Patients undergoing IVUS-guided PCI were more commonly treated
with a two stent technique compared to angiography-guided PCI (43.2% vs. 35.0%), had
a larger main vessel mean stent diameter (standardized mean difference [SMD] 0.29 mm,
p <0.001), and larger side branch stent diameters (SMD 0.38mm, p <0.001). IVUS-
guided PCI was associated with a signiﬁcant reduction in the composite of death,
myocardial infarction (MI), and ST (6.9% vs. 12.0%, odds ratio [OR] 0.137, 95%
conﬁdence interval 0.023-0.825, p ¼ 0.030, Figure). IVUS-guided PCI was also asso-
ciated with a signiﬁcant reduction in death (OR 0.519, p<0.001) and stent thrombosis
(OR 0.218, p¼0.034) compared to angiography-guided PCI.acts/POSTER/Meta-Analyses and Reviews B251
